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Abstract— Background: Elevated blood glucose (BG) 
concentrations (Hyperglycaemia) are a common 
complication in critically ill patients. Insulin therapy is 
commonly used to treat hyperglycaemia, but metabolic 
variability often results in poor BG control and low BG 
(hypoglycaemia). Objective: This paper presents a model-
based virtual trial method for glycaemic control protocol 
design, and evaluates its generalisability across different 
populations. Methods: Model-based insulin sensitivity (SI) 
was used to create virtual patients from clinical data from 
three different ICUs in New Zealand, Hungary, and 
Belgium. Glycaemic results from simulation of virtual 
patients under their original protocol (self-simulation) and 
protocols from other units (cross-simulation) were 
compared.  Results: Differences were found between the 
three cohorts in median SI and inter-patient variability in 
SI. However, hour-to-hour intra-patient variability in SI 
was found to be consistent between cohorts. Self and cross-
simulation results were found to have overall similarity and 
consistency, though results may differ in the first 24-48 
hours due to different cohort starting BG and underlying 
SI. Conclusions and significance: Virtual patients and the 
virtual trial method were found to be generalisable across 
different ICUs. This virtual trial method is useful for in 
silico protocol design and testing, given an understanding of 
the underlying assumptions and limitations of this method.  
Index Terms—Glycaemic control, virtual trials, insulin 
sensitivity 
I. INTRODUCTION 
ritically ill patients often experience sustained stress 
induced hyperglycaemia (high blood sugar) and high 
glycaemic variability due to their critical condition [1-4]. 
Hypoglycaemia (low blood sugar), hyperglycaemia and high 
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glycaemic variability have each been independently linked to 
increased morbidity and mortality in intensive care units (ICU) 
[5-11]. Glycaemic control has demonstrated the ability to 
improve blood glucose (BG) outcomes, and reduce morbidity 
and mortality [12-15], based on the control of glycaemic levels 
[10, 16-20]. However, several studies have failed to repeat these 
positive results [21-23], often with significantly increased 
hypoglycaemia [11]. The main issue is that ICU patients are 
highly variable in their response to insulin, particularly in the 
first 48 hours of stay [24-26], which can make managing 
glycaemia difficult as patient condition evolves [27]. 
In this regard, model-based glycaemic control methods have 
recently shown good safety and performance [28-33]. Their 
main advantage is the use of a computer model to identify 
patient-specific insulin sensitivity (SI), which quantitatively 
describes patient response to insulin. In this way model-based 
protocols can better account for inter- and intra- patient 
variability when dosing insulin, in ways that many non-model-
based protocols simply cannot. However, given a validated 
model, these protocols are only as good as the ability to design 
the protocol for safe, effective glycaemic control. 
Assessing glycaemic control protocols in silico using 
clinically validated models and virtual trial methods enables the 
ability to design new protocols or assess and improve existing 
protocols, to optimize safety and quality of glycaemic control. 
Virtual trials utilise SI to simulate per-patient BG response to 
protocolised insulin treatments, and thus allow the assessment 
of hypo- and hyper- glycaemic risks and glycaemic variability. 
In silico design is also much faster and more efficient than 
controlled clinical testing on patients, with far less patient risk. 
Thus, a protocol can be optimized safely and rapidly before 
validation clinical pilot tests on patients. Importantly, this 
approach usually requires local clinical data to create virtual 
patients, characterised by time-varying insulin sensitivity, on 
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which to test these protocols [34-36]. Without this data, it is not 
possible to be sure if a protocol will, even with good 
compliance, translate successfully to another ICU. 
The objective of this paper is to assess the potential of 
independent (non-local) cohorts to generate virtual patients and 
simulate outcomes of glycaemic control protocols. This will be 
done in two parts: 
1) Analysis of model-based insulin sensitivity (SI) and its 
variability in three different ICU cohorts. 
2) Use of SI to create virtual patients for simulation, both 
with the original protocol (Self-Simulation) and protocols 
from other cohorts (Cross-Simulation), where results are 
compared to the clinical data for that protocol and cohort. 
The first examines underlying metabolic 
similarities/differences between the cohorts, and the second 
assesses the impact of these similarities and differences in 
assessing glycaemic control outcomes in virtual patient 
simulation. Hence, these two objectives test the 
interchangeability of virtual patients for virtual trial testing 
across units, cohorts and protocols, where the greater the 
generality, the easier it is to test and design new solutions using 
virtual patients.  
II. PATIENT DATA, COHORTS, AND PROTOCOLS 
Retrospective clinical data from three independent cohorts of 
20 critically ill patients were used for this study from 3 mixed-
medical ICU’s in Belgium, Hungary, and New Zealand. 
Patients were selected from clinical data records in each ICU 
based on similar BG data density required to create the 
equivalent, good quality virtual patients [37]. This criterion 
ensures more consistent measurement of true similarity or 
differences of metabolic differences between cohorts [38, 39]. 
Diagnosed diabetic patients were excluded. Other selection 
criteria for patients were: (1) glycaemic control for at least 60 
hours; (2) insulin administration at the beginning of glycaemic 
control; (3) at least 10 BG measurements during control, every 
4 hours (on average, but preferably more frequent), to allow 
good virtual patients to be created. Clinical data only covers 
time when insulin was being administered regularly, and insulin 
weaning protocols differed between units. Typically insulin 
therapy is completed well before ICU discharge. Clinical data 
was limited to a maximum of 120 hours (5 days) per patient, to 
prevent data from the more variable first 24 hours being 
swamped by more stable long glycaemic control episodes. This 
also prevented a few longer stay patients from dominating the 
outcome statistics. The total hours per cohort in Table 1 are 
approximately the 2000-2500 hours required to quantify 
metabolic level and variability in [38].  
All three cohorts are treated differently, and they are not 
intentionally clinically matched by APACHE code, diagnosis 
or other metrics (this data was not available for the Belgian 
cohort), although age is similar. Stage one of the analysis will 
assess metabolic similarity of these three cohorts. Thus, these 
three cohorts will provide a robust test of the hypothesis of 
interchangeability across different mixed-medical ICU’s and 
countries. Cohort details are shown in Table 1, and from here 
forward, the cohorts are denoted: Hungary (HU), New Zealand 
(NZ) and Belgium (BE). Although insulin delivery rates are 
similar between cohorts, nutritional dextrose delivery is very 
different (Table 1, Figure 1). Between the NZ and HU cohorts, 
APACHE II scores are very different. This data was not 
available for the BE cohort. 
A. Belgium (BE) 
The first cohort is from the Centre Hospitalier Universitaire 
TABLE I 
COHORT DETAILS. DATA ARE SHOWN AS MEDIAN[IQR] WHERE APPROPRIATE. 
Parameters New Zealand (NZ) Hungarian (HU) Belgian (BE) 
Num patients 20 20 20 
Total hours 1915 2000 2222 
Age (years) 65.0 [54.8-68.5] 66.5 [53.8- 70.0] 66.0 [51.8-71.8] 
Gender (M/F) 14/6 14/6 9/11 
APACHE II Score [IQR] 24 [ 19 – 28] * 33 [29 – 37]** N/A 
ICU LoS [IQR] (days) 20.0 [7.2 - 35.7]* 14.0 [8.2 - 19.8]** N/A 
Time on Protocol (h) 139.2 [82.8-216.8] 111.0 [77.1-192.1] 196.9 [114.9-291.0] 
Starting BG [mmol/L] 10.8 [9.0 – 13.9] 8.2 [6.9 – 9.6] 8.5 [7.3 – 9.9] 
Diabetic None None None 
Insulin dose (U/hr) 3.0 [1.5 - 4.5] 3.0 [1.5 - 5.0] 3.0 [2.0 - 5.5] 
Glucose Intake (g/hr) 6.1 [4.0 - 6.7] 8.2 [6.0 - 10.6] 9.7 [8.3 - 11.3] 
Model based SI: (L/mU/min x 10-4)    
Median SI [IQR] 3.2 [2.4 – 4.4] 4.8 [3.5 – 6.7] 2.0 [0.8 – 4.2] 
Median hour-to-hour ΔSI [IQR] 0.04 [-0.3 – +0.4] 0.05 [-0.4 – +0.4] 0.01 [-0.2 – +0.2] 
Median absolute hour-to-hour ΔSI [IQR] 0.3 [0.1 – 0.7] 0.4 [0.2 – 0.8] 0.2 [0.1 – 0.4] 
Median [IQR] Per-patient Median SI  3.2 [2.8 – 3.7] 5.1 [3.8 – 5.7] 3.9 [3.1 – 4.9] 
Model % fitting error [IQR] -0.6 [-2.2 – 0.8] 0.1 [-1.3 – 1.5] 0.0 [-1.1 – 1.0 ] 
*This data was available for 17/20 patients. **This data was available for 15/20 patients. N/A – this data was not available for the BE cohort. 
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of Liège (CHU) ICU, Belgium. In this cohort, the standard of 
care glycaemic control protocol was a sliding scale that dosed 
insulin based on the patient’s BG level and the previous insulin 
dose [40]. The protocol applied at CHU of Liège targets the 5.6-
8.3 mmol/L (100-150 mg/dL) band, and is characterized by an 
insulin infusion-only approach with a 1- or 4- hour time interval 
between BG measurements. Insulin rate is adjusted depending 
on current and previous BG level and current insulin infusion 
rate. However, it is limited by an inability to reduce insulin 
infusions until BG is within the target range. Enteral and 
parenteral nutrition is decided by clinicians and ICU practice 
with glucose boluses specified for BG < 2.2 mmol/L. BG 
measurements are made hourly until BG values are stable in the 
band, and then 4-hourly. Full details are given in [40]. 
B. New Zealand (NZ) 
The second cohort is from the Christchurch Hospital ICU, 
New Zealand, which uses the stochastic model-based STAR 
glycaemic control protocol [32, 33, 41]. The STAR protocols 
adjust both insulin and nutrition levels [32, 41] and measures 
hourly when outside the 4.4-8.0 mmol/L (80-144 mg/dL) band, 
and up to 3-hourly within the band based on nursing choice of 
intervention interval. The goal is to control BG with a 5% risk 
of BG < 4.4 mmol/L (80 mg/dL) for each intervention and to 
otherwise maximize nutrition given towards a target of 25 
kcal/kg/day, as per ACCP and ESPEN guidelines [42, 43]. 
Insulin is typically delivered as boluses every hour via an 
infusion pump.  
STAR utilizes stochastic forecasting of likely BG outcomes 
based on models of metabolic variability observed across a 
representative clinical data set. Hour-to-hour metabolic 
variability is characterized by a model-based insulin sensitivity 
(SI) parameter, and models of variability in SI allow subsequent 
forecasting of likely BG outcomes for the next 1, 2, and 3 hours 
[38]. These models can be used to dose insulin based on risk of 
glycaemic outcomes, and in particular limiting the risk of 
BG<4.4 mmol/L to 5% or less [32, 41]. The stochastic SI 
forecasting model used by this protocol is based on a 
retrospective reference population [38]. Insulin is automatically 
stopped by the STAR protocol when high insulin sensitivity 
indicates exogenous insulin is no longer required. Complete 
details on the STAR control framework can be found elsewhere 
[32, 41]. 
C. Hungary (HU) 
The third cohort is from Kálmán Pándy Hospital ICU, 
Hungary, which also uses STAR, although differently within 
the same framework. In the Hungarian cohort a STAR-
framework (STARHu) delivers insulin as an intravenous 
infusion and uses a significantly higher carbohydrate nutrition 
formula than the New Zealand ICU. Patients are transitioned 
from early aggressive parenteral nutrition to enteral nutrition as 
their stay progresses. Hence, it has a similar 5% risk of BG<4.4 
mmol/L, but delivers insulin and nutrition very differently. The 
stochastic model of SI used was the same as that used in NZ. 
Insulin is automatically stopped by the STAR protocol when 
high insulin sensitivity indicates exogenous insulin is no longer 
required. 
III. PHYSIOLOGICAL MODEL AND VIRTUAL PATIENTS 
The model used to create virtual patients is the clinically 
validated intensive care insulin, nutrition and glucose (ICING) 
model [44-46]:  









Fig. 1.  First 24 hours of clinical data for a) NZ cohort, b) HU cohort, and c) BE cohort. Dashed lines show the 5th and 95th percentiles of BG over time, and the 
lowermost dotted line denotes the formal definition for hypoglycemic threshold (2.2 mmol/L). Average insulin dose and total dextrose (parenteral and enteral) intake 
is shown in 6 hour blocks.  
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𝑃𝑃(𝑡𝑡) = min(𝑑𝑑2𝑃𝑃2,𝑃𝑃𝑚𝑚𝑚𝑚𝑒𝑒) + 𝑃𝑃𝑃𝑃𝐶𝐶(𝑡𝑡) (4) 
?̇?𝑃1(𝑡𝑡) = −𝑑𝑑1𝑃𝑃1 + 𝑃𝑃𝐸𝐸𝐶𝐶(𝑡𝑡) (5) 
?̇?𝑃2(𝑡𝑡) = −min (𝑑𝑑2𝑃𝑃2,𝑃𝑃𝑚𝑚𝑚𝑚𝑒𝑒) + 𝑑𝑑1𝑃𝑃1 (6) 
𝑢𝑢𝑒𝑒𝑒𝑒(𝐺𝐺) = min (max (𝑢𝑢𝑚𝑚𝑚𝑚𝑒𝑒 , 𝑘𝑘1𝐺𝐺(𝑡𝑡) + 𝑘𝑘2),𝑢𝑢𝑚𝑚𝑚𝑚𝑒𝑒) (7) 
The key variables and model parameters are described in 
Table 2. With the exception of model-based insulin sensitivity, 
SI(t) (SI), all parameters are fixed and have been previously 
identified from other studies and data cohorts [44, 46, 47], with 
details in an online appendix to this paper.  
This model-based insulin sensitivity, SI(t) (SI), is identified 
hourly, using the integral based fitting method [48]. SI is 
representative of ‘whole body’ underlying metabolic condition, 
and captures patient-specific deviation from model population 
parameters. Previous work has shown it to be relatively 
independent of both insulin and nutrition inputs [35]. It can thus 
be used to calculate the likely BG response to treatments other 
than those given clinically. This process is called a virtual trial, 
and has been used to design protocols for use in clinical 
situations [35, 49]. 
To generate virtual patients, clinical data, comprising BG 
measurements and insulin and nutrition inputs, is used with 
model Equations (1)-(7) to identify a model-based SI(t) profile 
for each patient using integral-based methods [48, 50]. These 
profiles can be used to simulate the response to a new or 
modified set of insulin and/or nutrition inputs, generating a new 
G(t) (BG) profile. This virtual patient and virtual trial process 
is illustrated in Figure 2. 
IV. ANALYSES 
A. Comparison of SI 
Model-identified SI values are presented to assess the 
metabolic similarity of the cohorts. Cumulative distributions 
are used to assess cohort SI and cohort-wide variability, where 
offset between curves shows difference in median SI, and the 
slope denotes the tightness of the distribution. At a given 
cumulative fraction, F, the results show the median, inter-
quartile range, and 90th percentile range in SI for the per-patient 
(100xF)th percentile SI values. This is a measure of inter-patient 
variability within each cohort. 
Hour-to-hour SI variability is also assessed, using hour-to-
hour stochastic models [38, 39], which are plotted with the x 
axis showing SI at time n and the y axis showing SI at time n + 
1. These stochastic hour-to-hour variability plots give a 
measure of intra-patient metabolic variability [38, 39], which 
TABLE II 
KEY VARIABLES OF THE ICING METABOLIC GLUCOSE MODEL 
 UNITS DESCRIPTION 
Physiological states 
G(t) mmol/l Blood glucose concentration 
I(t) mU/l Plasma insulin concentration 
Q(t) mU/l Interstitial insulin concentration 
𝑃𝑃1(𝑡𝑡) mmol Glucose in stomach 
𝑃𝑃2(𝑡𝑡) mmol Glucose in gut 
External inputs 
𝑃𝑃𝑃𝑃𝑃𝑃(𝑡𝑡) mmol/min Parenteral glucose intake 
𝑃𝑃𝐸𝐸𝑃𝑃(𝑡𝑡) mmol/min Enteral glucose appearance 
𝑢𝑢𝑒𝑒𝑒𝑒(𝑡𝑡) mmol/min Exogenous Insulin administration 
Model parameters 
SI(t) l/mU/min Insulin sensitivity 
𝛼𝛼𝐺𝐺  1/65 l/mU 
Saturation of insulin-mediated glucose 
uptake 
𝑉𝑉G 13.3 L Glucose distribution volume 
𝐸𝐸𝐺𝐺𝑃𝑃 1.16 mmol/min Endogenous glucose production (hepatic) 
𝐶𝐶𝐶𝐶𝑆𝑆 0.3 mmol/min Glucose uptake by central nervous system 
𝑑𝑑1 -ln(0.5)/20 min-1 
Rate parameter: gastric emptying of 
stomach to gut 
𝑑𝑑2 -ln(0.5)/100 min-1 
Rate parameter: glucose absorption for 
gut to bloodstream 
𝑃𝑃𝑚𝑚𝑚𝑚𝑒𝑒 6.11 mmol/min 
Maximum glucose absorption rate from 
gut 
𝑥𝑥𝐿𝐿 0.67 
Fractional first pass hepatics insulin 
clearance from portal vein 
𝑛𝑛𝐿𝐿 0.1578 min-1 
Rate parameter: general hepatic insulin 
clearance 
𝛼𝛼𝐼𝐼 1.7x10-3 l/mU Saturation of hepatics insulin clearance 
𝑛𝑛𝐾𝐾  0.0542 min-1 
Rate parameter: kidney clearance of 
insulin 
𝑛𝑛𝐶𝐶  0.0075 min-1 
Rate parameter: cellular degradation of 
internalised insulin 
𝑛𝑛𝐼𝐼 0.0075 min-1 
Rate parameter: diffusion of insulin 
between plasma and interstitium 
𝑢𝑢𝑒𝑒𝑒𝑒 mU/min Pancreatic insulin secretion 
𝑘𝑘1 
14.9 
mU·l/mmol/min Insulin secretion model parameter 
𝑘𝑘2 -49.9 mU/min Insulin secretion model parameter 
𝑢𝑢𝑚𝑚𝑚𝑚𝑒𝑒 16.7 mU/min Minimum insulin secretion 
𝑢𝑢𝑚𝑚𝑚𝑚𝑒𝑒 266.7 mU/min Maximum insulin secretion 




Fig. 2.  Virtual trial scheme for self- and cross simulation for the three cohorts 
and protocols. The full simulation scheme is shown for the NZ cohort only, but 
generalises to the BE and HU cohorts. Self-simulation is used to indicate ability 
to replicate clinical data. Cross simulation results indicate generalisability of 
virtual trial methods. 
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can be a leading cause of poor control and hypoglycaemia [27].  
If metabolic level and/or variability are similar between cohorts 
then the SI levels and/or stochastic models will be similar or 
identical. Consistency between ICUs in SI behaviour would 
imply that a perfectly matched cohort or data from a specific 
ICU is not necessary to obtain valid virtual trial results for 
another ICU, and a small, 20-patient virtual cohort could 
generalize and capture the metabolic behaviour of a similar 
mixed-medical ICU. 
B. Virtual Trial Simulation 
To examine the relationship between virtual patients and 
glycaemic control outcomes virtual trials are used. Glycaemic 
outcomes are a function of SI and its variability, as well as the 
insulin-nutrition protocol used. If virtual patients are 
generalisable, glycaemic virtual trial control outcome results 
will be consistent for all three cohorts (HU, NZ, BE) on that 
protocol. The results are presented as cumulative distribution 
functions (CDFs) of BG values.  This virtual trial simulation 
structure is shown in Figure 3.  
Testing a virtual patient cohort on the same protocol that 
yielded the data used to create the virtual patient (self-
simulation) should return exactly the clinical BG data used to 
generate it, with differences due to model error (also observable 
as fitting error) and/or lack of compliance in following the 
protocol clinically. Thus, self-simulation captures the model 
error and any un-modelled non-compliance to the clinical 
protocol.  
Cross-simulation is a technique for assessing how results of 
an analysis will generalize to a separate, independent virtual 
patient cohort. In this case, this step consists in applying a 
clinical protocol to a series of virtual patients created from a 
cohort on which the protocol was never clinically tested. If 
patients are matched in terms of metabolic dynamics and if the 
virtual trial method is correct, then the in silico results and 
clinical data would theoretically match or be very similar, 
showing the generalisability or robustness of the approach. 
Differences would be due to underlying metabolic differences, 
and the interaction of model-based SI with the protocol. 
Each of the three protocols, where STAR in Hungary and 
New Zealand are denoted STAR-Hu and STAR-NZ 
respectively, was simulated on virtual patients from all other 
cohorts (HU, NZ, BE). In all cases, the virtual trial simulation 
was only allowed to modulate insulin, as the BE glycaemic 
 
Fig. 3.  Virtual patient generation and virtual trial methodology. Virtual patients 
are comprised of the insulin sensitivity (SI) traces fitted from clinical data. 
Different glycaemic control protocols can be tested in silico to assess likely 




Fig. 4.  Per patient median insulin sensitivity (SI) CDFs, for each cohort: a) NZ cohort; b) HU cohort; c) BE cohort; and d) the median per-patient SI CDFs 
overlaid for comparison. All values identified from data and the ICING model of Equations (1)-(7). In a) – c) the 5th – 95th and 25th – 75th percentile ranges are 
shown. F(x) is the cumulative fraction of data less than or equal to the corresponding SI, as per standard CDF definition. 
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control protocol did not explicitly modify or determine 
nutritional intake. In simulation nutrition was set at what was 
clinically given. 
V. RESULTS  
A. Metabolic Similarity: Inter-Cohort Insulin Sensitivity and 
Variability 
To examine underlying metabolic similarities and 
differences between the BE, HU, and NZ cohorts, model-based 
SI is examined. Whole cohort and per-patient median SI is 
given in Table 1, along with the median hour-to-hour change in 
SI, and the median absolute hour-to-hour change in SI. The 
median hour-to-hour change in SI is ~0 for each cohort, while 
the median absolute hour-to-hour change, reflecting both 
increase and decrease in SI, in SI is approximately 5 – 10% of 
the median SI value. 
Figure 4 shows the range of per-patient CDFs SI for each 
cohort with the median SI overlaid. Median SI is different 
within each cohort, indicating different degrees of underlying 
metabolic response to glucose and insulin treatments.  
Steeper CDFs indicate lower cohort wide variability as a 
greater proportion of time is spent around a particular SI range. 
The consistent slope of the CDFs in Figure 4d shows each 
cohort is similar in the tightness of the middle ~60% of the data. 
However, in Figure 4c the NZ cohort has slightly lower inter-
patient variability compared to the others, as seen in the lower 
spread of the 25th – 75th and 5th – 95th percentile SI CDFs. In 
contrast, the HU cohort has the widest set of per-patient SI 
CDFs and thus the greatest inter-patient variability. Overall, the 
magnitude of the model-based SI, and thus the metabolic ability 
to remove glucose from the blood, is different for each cohort, 
as seen when comparing medians and offset from other CDFs. 
SI is different within each cohort, and while cohort wide 
variability is similar, the degree of inter-patient variability 
differs between cohorts.  
Figure 5 shows the hour-to-hour change in insulin sensitivity 
 
Fig. 5.  Stochastic insulin sensitivity models for hour “n” (x-axis) and hour “n+1” (y-axis) showing the data (dots) and the 5th-95th percentile range (light), IQR 
(dark) and median (dashed) probability bounds for stochastic models for the three cohorts, where: a) NZ cohort; b) HU cohort; c) BE cohort; and d) All three 
cohorts overlaid with the median, 5th, and 95th percentile lines shown. All data were found using the ICING model of Equations (1)-(7) to identify hourly SI values. 
 
TABLE III 
NEW ZEALAND PROTOCOL: CROSS SIMULATION RESULTS, CLINICAL DATA SHADED. RESULTS ARE FOR THE FULL (MAX 120 HRS) PATIENT EPISODE 
New Zealand (NZ) protocol NZ – Clinical data Cross validation on HU cohort 
Cross validation on 
BE cohort 
BG measures / day 13.1 12.9 14.2 
Mean time between measurements (hr) 1.8 [1.0 - 2.8] 2.0 [1.0 - 3.0] 1.0 [1.0 - 2.0] 
Median BG [IQR] (mmol/L) 6.7 [6.0 – 7.3] 6.7 [6.2 – 7.4] 6.9  [6.3 – 7.6] 
Time in 4.4-8.0 mmol/L band (%) 85.4 83.1 81.6 
Median [IQR] exogenous insulin bolus  (U/hr) 3.0 [1.5 - 4.5] 2.5 [1.5 - 4.0] 4.0 [2.0 - 6.0] 
Per-Patient Median BG (mmol/L) 6.6 [6.4 - 6.8] 6.7 [6.5 - 6.9] 6.9 [6.6 - 7.1] 
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across each of the cohorts, The median, IQR, and 5th – 95th 
percentile range indicate the potential variability of SIn+1 for any 
given SIn value. While data scarcity above an SI of greater than 
~10 -3 L/mU/min results in wide and variable bounds, what is 
interesting is that below this threshold each of the cohorts 
display similar behaviour, as shown in Figure 5d. Thus, while 
median SI may vary between cohorts, hour-to-hour variability 
across the common SI range is consistent.  
Figures 4 and 5 thus suggest that patient cohorts may differ 
in the SI range in which they spend most of their time, and have 
different inter-patient metabolic variability. However, 
underlying intra-patient metabolic variability is much more 
consistent. The hour-to-hour intra-patient variation between 
cohorts is very similar despite differences between protocols 
and clinical implementation, different metabolic SI levels in 
Figure 4, and despite not matching the cohorts for diagnostic 
code or other factors. Consequently, hour-to-hour changes in SI 
are independent from protocol, and are instead patient-specific, 
TABLE IV 
HUNGARIAN PROTOCOL: CROSS SIMULATION RESULTS, CLINICAL DATA SHADED. RESULTS ARE FOR THE FULL (MAX 120 HRS) PATIENT EPISODE 
Hungarian (HU) protocol Cross validation on NZ cohort HU – Clinical data 
Cross validation on BE 
cohort 
BG measures / day 13.0 12.8 14.7 
Mean time between measurements (hrs) 2.0 [1.0 - 3.0] 1.7 [1.0 - 2.9] 2.0 [1.0 - 2.0] 
Median BG [IQR] (mmol/L) 6.9 [6.3 - 7.6] 6.6 [5.9 - 7.4] 6.9 [6.4 - 7.6] 
Time in 4.4-8.0 mmol/L band (%) 81.5 81.0 81.4 
Median [IQR]exogenous insulin rate  (U/hr) 3.0 [1.5 - 4.5] 3.0 [1.5 - 5.0] 4.5 [2.5 - 8.0] 
Per-Patient Median BG (mmol/L) 6.8 [6.6 - 7.1] 6.5 [6.3 - 6.9] 6.9 [6.6 - 7.2] 
 
TABLE V 
BELGIAN PROTOCOL: CROSS SIMULATION RESULTS, CLINICAL DATA SHADED. RESULTS ARE FOR THE FULL (MAX 120 HRS) PATIENT EPISODE 
Belgian (BE) protocol Cross validation on  New Zealand cohort 
Cross validation on 
HU cohort BE – Clinical data 
BG measures / day 9.5 9.4 9.9 
Mean time between measurements (hrs) 4.0 [1.0 - 4.0] 4.0 [1.0 - 4.0] 1.0 [1.0 - 4.0] 
Median BG [IQR] (mmol/L) 7.6 [6.5 - 8.5] 7.3 [6.4 - 8.2] 7.4 [6.3 - 8.5] 
Time in 4.4-8.0 mmol/L band (%) 58.2 69.1 62.9 
Median [IQR]exogenous insulin rate  (U/hr) 2.0 [0.5 - 3.5] 3.0 [1.5 - 3.5] 3.0 [2.0 - 5.5] 




Fig. 6.  Results of self- and cross- simulation: blood glucose (BG) CDFs for the clinical data and all 3 virtual cohort simulations (HU, NZ, BE). Shaded regions 
represent the glycaemic target band for that protocol for reference. Panel a) is the NZ protocol (see Table 3); b) is the HU protocol (see Table 4); and c) is the BE 
protocol (see Table 3); and d) compares all clinical data for completeness. F(x) is the cumulative fraction of data less than or equal to the corresponding BG, as per 




but similar across different cohorts. An important result is that, 
despite differences in the median cohort SI, stochastic 
forecasting models, such as those pictured in Figures 5a – c, are 
likely interchangeable and generalisable, potentially indicating 
a consistent physiological response.  
B. Protocol simulation using Virtual Trials  
Virtual trial results show the interaction of the model and 
model-based insulin sensitivity with glycaemic control 
protocols. Figure 6 and Tables 3 - 5 show the self- and cross-
simulation results for each of the cohorts and protocols. Self-
simulation results show good matching in the STAR-NZ and 
STAR-Hu cohorts. Overall, self-validation results show that the 
ICING model can capture key BG dynamics, and reproduce 
clinical results in the case of protocolised insulin and nutrition 
treatments.  
 In the case of the BE cohort shown in Figure 6c, differences 
between the clinical and self-simulation results are attributed to 
clinical non-compliance, where 20-30% of interventions were 
modified slightly from protocol [40], combined with a lack of 
protocolisation around feed changes. The outcome is slightly 
higher clinical BG value than in the self- or cross- simulation 
results of Figure 6c.  
Cross-simulation results show the interaction of SI and SI 
variability with a protocol on which the virtual patients were 
not treated. Cross-simulation result comparisons for all three 
protocols are similar, with median and IQR values falling 
within expected measurement error (< 5%). This results shows 
that the virtual trial model and methods are able to yield median 
(cohort and per-patient) and variability in predicted cohort BG 
outcomes that are very similar to the clinical data in all cases. 
If only the first 24 hours of simulation are considered, cross 
simulation results show good matching above the ~25th 
percentile of BG outcomes for the STAR-HU and STAR-NZ 
protocols (Figures 7a and 7b), with similar modest deviation as 
in Figure 6 for the BE protocol (Figure 6c). Figure 8 shows that 
although by 24 hours cohort results begin to match well, during 
the first 20 hours BG outcomes are very cohort specific due to 
the interactions and differences in cohort starting BG and SI 
level. These starting differences between cohorts are most 
clearly seen in the ability for the protocols to reach lower 
extremes of glycaemic behaviour, where the results below the 
25th percentile in Figure 8 a) and b) tend to spread more. 
VI. DISCUSSION 
Previous work has validated the virtual trial method in 
matched [35] cohorts, and extended the analysis to a New 
Zealand mixed-medical ICU cohort and a Belgian 
cardiovascular ICU cohort [37]. This work extends a virtual 
trial method to three unmatched medical ICU cohorts from 
three different countries and clinical practices, and examines 
the generalisability of virtual patient cohorts and the strengths 
and limitations of the virtual trial method. If virtual patient 
cohorts, created from clinical data, were interchangeable 
between ICUs, then it would be possible to significantly extend 
the use of virtual patients. This outcome would reduce the need 
for high quality clinical data and provide a common foundation 
glycaemic control design tool, similar to those used in Type 1 
Diabetes research [51].  
We hypothesised that virtual trials for protocol performance 
determination can be carried out on interchangeable, 
generalised cohorts. The results presented here show good 
matching between cross-simulated virtual trial simulations 
 
Fig. 7.  Results of self- and cross- simulation for the first 24 hours only: blood glucose (BG) CDFs for the clinical data and all 3 virtual cohort simulations (HU, 
NZ, BE). Shaded green region represents the glycaemic target band for that protocol for reference. Panel a) is the NZ protocol (see Table 3); b) is the HU 
protocol (see Table 4); and c) is the BE protocol (see Table 3); and d) compares all clinical data for completeness. F(x) is the cumulative fraction of data less than 




across a range of protocols and cohorts, as indicated by the 
overlap of the CDF’s in Figure 6. These results suggest that 
overall performance of a glycaemic control protocol can be 
tested using virtual trials and a generalised cohort, without the 
need for local data collection. 
A significant result of this work was the similarity across 
cohorts in terms of SI variability, despite differences in median 
cohort SI distributions. This result is similar to previous results 
in two different cohorts, using protocols that differ from those 
presented here, where SI variability was similar despite the fact 
that median SI was different between the cohorts [37]. This 
median SI and inter-patient variability likely differs between 
units based on the severity and type of illness or injury, and a 
potentially wide range of other cohort and demographic factors. 
In contrast, the similarity in SI variability strongly suggests that 
this hourly variability, driven by counter-regulatory and stress 
response physiology, may be more general than other factors in 
determining patient-specific metabolic behavior.  
An added potential outcome of this study is that if a (larger) 
virtual patient cohort, sufficiently representative of intra-patient 
SI variability, could be created from multiple cooperating 
centres, there would not be a future need to build cohort specific 
forecasting models from retrospective data. The generality seen 
in Figure 5 indicates that this outcome could well be possible, 
although further work should look at specific sub-cohorts such 
as trauma or sepsis patients. Equally, arbitrary generalised 
virtual patients can be created based on clinically observed 
variability. While generalized population models go against the 
trend to make models more and more patient specific, these 
results show a good balance of exploiting generalisability to 
minimize clinical workload and data collection, while 
maintaining high safety and performance.  
A. Limitations on Virtual Trial Generalisability 
While this analysis suggests a good degree of generalisability 
in virtual trial cohorts, it is limited to 3 clinical cohorts. Further, 
this generalisability of virtual patient cohorts is subject to 
limitations and exclusion criteria based on protocol type and 
underlying assumptions.   
All three cohorts were observed to have similar insulin 
sensitivity variability, but different cohort median SI. It is this 
similarity across intra-patient 
insulin sensitivity variability 
that determines the similarity in 
long term cohort results. Thus, 
for any cohort matched in intra-
patient insulin sensitivity 
variability, similarity in 5 day 
virtual trial results is expected. 
This result reflects previous 
work using two clinically 
matched cohorts from a single 
intensive care unit, with very 
different insulin-nutrition 
treatments and glycaemic 
targets, but who were matched 
in underlying SI and SI 
variability [35]. Cohorts not 
matched in SI variability are 
likely to yield different 
glycaemic control results in 
virtual trials.  
Virtual trial results are not expected to be similar if protocols 
have limits on the maximum insulin dose much lower than the 
insulin dose at which insulin saturation effects ([52]) are 
observed. The protocol being tested must be flexible enough to 
allow a range of insulin doses, depending on underlying patient 
SI, whether it is being directly measured or not. For example, 
an insulin resistant patient will require higher insulin doses to 
achieve a target BG outcome than a more insulin sensitive 
patient. A strict sliding scale where insulin dose is directly 
proportional to BG will not likely have this flexibility, and 
highly resistant or highly fed patients will likely remain high in 
BG if insulin dose is very limited. On the other hand, sliding 
scale protocols where the change in insulin dose is proportional 
to BG, such as the BE protocol in this paper or the protocols in 
the original validation paper [35], allow insulin doses to 
increase in patients with low SI.  
A limitation of this method is that virtual trials are not 
expected to give similar results in patients where the starting 
BG and the time taken to reduce BG to the protocol median BG 
and/or target range are very different between cohorts, 
especially over the first 24-48 hours. These early outcomes are 
heavily influenced by patient and cohort SI and nutritional 
delivery. While in these results the 24 hour BG outcome results 
were also very similar, the 12 hour results are very different 
(Figure 8) as the time taken for each cohort to be lowered into 
the target range differs based on starting BG and cohort median 
insulin sensitivity. The shorter the time to lower BG into the 
target range relative to the length of each virtual patient, the 
closer virtual trial BG outcomes will be in cohorts with different 
median SI or feed rates.  
In addition, over the first 24 hours the greatest variability in 
low blood glucose outcomes was observed between cohorts. 
This outcome suggests that when designing and testing 
protocols for use in a different cohort, virtual trials with 
interchanged cohorts may not fully or accurately reflect safety 
and performance over the first 12-24 hours, which can be 
important to outcome [53]. In addition, in terms of clinical 
compliance and equipoise over the adoption or use of a new 
protocol, these first hours can be crucial to overall protocol 
 
Fig. 8.  First 72 hours of cumulative median BG data for the two most different protocols: a) STAR-NZ, and b) the BE 
titration protocol. 
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performance and uptake. For this reason, it may be wise to 
simulate potential BG outcomes in a cohort of ‘difficult’ 
patients as well as a generalised cohort, to determine a worst 
case protocol design outcome for protocol results over the first 
24 hours. 
Finally, generalised virtual trial methods are not able to give 
estimations of total insulin or nutrition delivery, as this delivery 
is cohort specific and will depend on underlying condition and 
SI, and clinical preferences in nutrition type and range. While 
protocol performance is generally of more concern than its 
consumables, clinical preference and goals for total feed 
delivery may be an obstacle for protocol implementation where 
a glycaemic control protocol modulates both glucose and 
insulin. Results around total insulin and nutrition delivery from 
generalised virtual trials should be treated with caution where 
the underlying SI from the targeted cohort is unknown. 
B. Study Limitations and Future Work 
This study utilized the ICING model. This model, as with all 
models, has underlying assumptions and has regions for BG and 
insulin-nutrition interventions in which it is most accurate. In 
this case, many model parameters are fixed as they are not 
currently identifiable using available bedside data. As a result, 
the SI parameter reflects both peripheral insulin sensitivity and 
patient-specific deviation from population-based model 
parameters, all of which could be time-varying. It thus lumps 
changes in patient response into the SI value. However, the fact 
that SI has been validated in its effective clinical use for 
glycaemic control, and can be used in virtual trials to accurately 
simulate clinical outcomes [35, 41], suggests that the model 
overall captures key dynamics and dynamic shapes. This model 
thus balances the need for practical bedside identifiability [54] 
and use with model accuracy to underlying physiology [54, 55] 
A primary limitation of this study is the use of only 3 cohorts, 
and only 2 glycaemic control frameworks, from intensive care 
units that are primarily western in ethnic groups and clinical 
practice. The HU cohort had much higher APACHE II score 
than the NZ cohort, indicating differences in illness severity, 
but this score was not available for the BE cohort. These cohorts 
were drawn from different countries and clinical practices, and 
had different underlying SI. In future, these results should be 
tested on patient data cohorts from potential different ethic 
cohorts, such as those from Asian or Asia-Pacific intensive care 
units. Should SI variability prove to be similar across a wider 
range of ethnic origins, this work would provide a strong case 
for generalisable virtual trials to give a reasonable overview of 
likely BG outcomes. 
The use of unmatched cohorts was chosen by design to test 
the generalisability of the virtual patient methods tested and to 
help find the underlying reasons for successful validation. 
However, clinically matched cohorts would provide a stronger 
validation result as in [35], even if limited in application since 
local patient data would be required to create a local virtual 
cohort based on the evidence of results using matched cohorts. 
In this case, the cohorts are similar in age and do not have 
diagnosed diabetes patients, but are otherwise general.  
Two of the protocols used in this analysis, STAR-NZ and 
STAR-HU, were similar in design dynamic, if not in clinical 
use and delivery. These similarities and differences give an 
indication of how very different clinical implementation 
conditions and nutritional delivery can impact virtual trial 
results. In this case, STAR-NZ and STAR-HU are able to give 
similar clinical results despite differences in insulin delivery 
and nutrition rate. 
It is very difficult to completely or perfectly validate these 
results or any in silico virtual trial. An ideal real clinical trial 
would treat a patient, and then take them back in time to treat 
them differently, all else the same. In theory these results could 
be fully validated implementing all protocols clinically in each 
unit, preferably with strict compliance and matched cohorts. 
This outcome could only be achieved prospectively at some 
cost, and was not possible here. However, the results presented 
strongly suggest that relatively small 20 patient virtual trial 
cohorts can capture a majority of cohort outcomes, and that 
larger cohorts might do as well or better.  
VII. CONCLUSIONS 
Virtual patients were generated from clinical data from three 
different intensive care units using a glucose-insulin 
pharmacokinetic model. These virtual patients were used in 
virtual trials to test the generalisability of virtual patients and 
virtual trial methods across different ICUs. It was found that 
although cohort median insulin sensitivity was different 
between ICUs, hour-to-hour variability in this insulin 
sensitivity was similar. As a result, different virtual patient 
cohorts were able to closely replicate glycaemic control 
outcomes in virtual trials across different protocols. These 
results provide evidence for the generalisability of virtual 
patient cohorts and the virtual patient method to assess likely 
long-term glycaemic control outcomes during protocol design 
and testing. While generalisable, this virtual patient method has 
several important limitations, in that it may not accurately 
reflect cohort behaviour in the first 24 hours in some cohorts, 
and protocols tested must be sufficiently flexible to adapt to 
more resistant or highly fed patients. Overall, this paper 
presents results supporting a generalised virtual trial method, 
and discusses the strengths and limitations of this method.  
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